Study of the effect of anagliptin on glucose and lipid metabolism abnormality after the test meal loading.

Study of the effect of anagliptin on glucose and lipid metabolism abnormality after the test meal loading. - Study of the effect of anagliptin on glucose and lipid metabolism abnormality after the test meal loading.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011424

Enrollment

Registered

2013-08-09

Start date

2013-08-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impaired glucose tolerance. Type II diabetes mellitus.

Interventions

SUINY (Anagliptin)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age, gender unquestioned. 2. Patients in need of blood glucose control by DPP-4 inhibitors. 3. Outpatients. 4. Patients who will be able to obtain written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who used DPP-4 inhibitors within the last 3 months. 2. Patients with contraindication of anagliptin following: Patients who have a history of allergy due to anagliptin. Severe ketosis, diabetic coma or precoma, type I diabetes mellitus. Severe infection, before and after surgery, patients with severe trauma. 3. Patients on insulin. 4. Patients on rapid-acting insulin secretagogue. 5. Patients with severe renal failure and/or dialysis. 6. Patients with food allergy due to test meal component. 7. Patients who were judged to be inappropriate for the study by the investigator.

Design outcomes

Primary

Measure	Time frame
Amount of change of TAGE, ApoB48. Amount of change of iAUC.	—

Countries

Japan

Contacts

Public ContactJunji Kobayashi

Kanazawa Medical University General Internal Medicine

mary@kanazawa-med.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026